Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397659 | 1.00 | RORC (0.37) | RORCDRD2DRD1POLBTDP1 | |
| SCHEMBL17656944 | 0.75 | DRD2 (0.40) | RORCDRD2DRD1POLBTDP1 | |
| SCHEMBL8997679 | 0.71 | MTNR1A (0.32) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL2597463 | 0.70 | BRD4 (0.45) | — | |
| SCHEMBL50426 | 0.70 | KDM4E (0.49) | POLBTDP1MTNR1AMTNR1B | |
| SCHEMBL8116003 | 0.70 | SRD5A1 (0.47) | DRD1TDP1MTNR1AMTNR1BHTR2C | |
| SCHEMBL31137696 | 0.69 | DRD2 (0.43) | RORCDRD2DRD1POLBTDP1 | |
| SCHEMBL5400138 | 0.68 | CHRM2 (0.45) | POLB | |
| SCHEMBL17660751 | 0.68 | DRD2 (0.40) | RORCDRD2DRD1POLBTDP1 | |
| SCHEMBL28447625 | 0.67 | DRD2 (0.41) | RORCDRD2DRD1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431243-B | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119431243-A | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119431243-B | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119431243-A | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-9586904-B2 | Preparation of (−)-huperzine A | ZHEJIANG WANBANG PHARMACEUTICAL PLC. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586904-B2 | Preparation of (−)-huperzine A | ZHEJIANG WANBANG PHARMACEUTICAL PLC. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20160159745-A1 | PREPARATION OF (-)-HUPERZINE A | ZHEJIANG WANBANG PHARMACEUTICAL PLC. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159745-A1 | PREPARATION OF (-)-HUPERZINE A | ZHEJIANG WANBANG PHARMACEUTICAL PLC. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008088936-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159745-A1 | PREPARATION OF (-)-HUPERZINE A | CYP8B1, HBZ, CYP3A5 | RORC 355/4885DRD2 1810/4885DRD1 1081/4885 |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | RORC 955/4885DRD2 4572/4885DRD1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.